-continued

```
ggattcagtg cttgatccat gtccagagtc ttcagtttct gaatcctctt ctcttgtaat   6360

atcaagaata catttcccca tgcatatatt atatttcatc cttgaaaaag tatacatact   6420

tatctcagaa tccagccttt ccttccattc aacaattcta gaagttaaaa ctggggtaga   6480

tgctattaca gaggtagaat gcttcctaaa cccagaaatg ggggatctgc              6530


<210> SEQ ID NO 56
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: 3A4 heavy chain CDR2

<400> SEQUENCE: 56

Asp Ile Asn Pro Tyr Asn Gly Asp Thr Asn Tyr Asn Gln Lys Phe Lys
1               5                   10                  15
```

**1**. A method for treating cancer, the method comprising the steps of: (a) administering an anti-cancer therapeutic to a patient, (b) contacting a sample obtained from the patient with an anti-kidney associated antigen 1 (KAAG1) antibody or antigen binding fragment thereof, (c) detecting a complex formed by the antibody or antigen binding fragment thereof and a KAAG1- or KAAG1-variant expressing cell, and (d) administering a further anti-cancer therapeutic.

**2**. The method of claim **1**, wherein the anti-cancer therapeutic of step (d) is an anti-KAAG1 antibody or an antigen binding fragment thereof.

**3**. The method of claim **1**, wherein the anti-KAAG1 antibody or antigen binding fragment thereof of step (b) is a monoclonal antibody, a chimeric antibody, a hybrid antibody, a humanized antibody or a human antibody or an antigen binding fragment thereof.

**4**. The method of claim **1**, wherein the anti-KAAG1 antibody or antigen binding fragment thereof of step (b) comprises a heavy chain variable region comprising the CDRH1 amino acid sequence set forth in SEQ ID NO.:5, the CDRH2 amino acid sequence set forth in SEQ ID NO.:6 or in SEQ ID NO:56 and the CDRH3 amino acid sequence set forth in SEQ ID NO.:7 and a light chain variable region comprising the CDRL1 amino acid sequence set forth in SEQ ID NO.:8, the CDRL2 amino acid sequence set forth in SEQ ID NO.:9 and the CDRL3 amino acid sequence set forth in SEQ ID NO.:10.

**5**. The method of claim **1**, wherein the anti-KAAG1 antibody or antigen binding fragment thereof of step (b) comprises:

a. a heavy chain variable region having the amino acid sequence set forth in SEQ ID NO.:41 and a light chain variable region having the amino acid sequence set forth in SEQ ID NO.:33;

b. a heavy chain having the amino acid sequence set forth in SEQ ID NO.:49 and a light chain having the amino acid sequence set forth in SEQ ID NO.:43;

c. a heavy chain variable region having the amino acid sequence set forth in SEQ ID NO.:38 and a light chain variable region having the amino acid sequence set forth in SEQ ID NO.:33;

d. a heavy chain having the amino acid sequence set forth in SEQ ID NO.:46 and a light chain having the amino acid sequence set forth in SEQ ID NO.:43;

e. a heavy chain variable region having the amino acid sequence set forth in SEQ ID NO.:39 and a light chain variable region having the amino acid sequence set forth in SEQ ID NO.:33;

f. a heavy chain having the amino acid sequence set forth in SEQ ID NO.:47 and a light chain having the amino acid sequence set forth in SEQ ID NO.:43;

g. a heavy chain variable region having the amino acid sequence set forth in SEQ ID NO.:40 and a light chain variable region having the amino acid sequence set forth in SEQ ID NO.:33;

h. a heavy chain having the amino acid sequence set forth in SEQ ID NO.:48 and a light chain having the amino acid sequence set forth SEQ ID NO.:43;

i. a heavy chain variable region having the amino acid sequence set forth in SEQ ID NO.:41 and a light chain variable region having the amino acid sequence set forth in SEQ ID NO.:34;

j. a heavy chain having the amino acid sequence set forth in SEQ ID NO.:49 and a light chain having the amino acid sequence set forth in SEQ ID NO.:44;

k. a heavy chain variable region having the amino acid sequence set forth in SEQ ID NO.:38 and a light chain variable region having the amino acid sequence set forth in SEQ ID NO.:34;

l. a heavy chain having the amino acid sequence set forth in SEQ ID NO.:46 and a light chain having the amino acid sequence set forth in SEQ ID NO.:44;

m. a heavy chain variable region having the amino acid sequence set forth in SEQ ID NO.:39 and a light chain variable region having the amino acid sequence set forth in SEQ ID NO.:34;

n. a heavy chain having the amino acid sequence set forth in SEQ ID NO.:47 and a light chain having the amino acid sequence set forth in SEQ ID NO.:44;

o. a heavy chain variable region having the amino acid sequence set forth in SEQ ID NO.:40 and a light chain variable region having the amino acid sequence set forth in SEQ ID NO.:34;